{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:25:24Z","timestamp":1792801524994,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"HK inno.N Corp"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74003-5","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:52:00Z","timestamp":1727927520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment"],"prefix":"10.1038","volume":"14","author":[{"given":"Moon-Seung","family":"Soh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-heon","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Su","family":"Hyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Joong","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo-Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngkeun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ju","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jea","family":"Tahk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"74003_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. 2023 ESH guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens.41, 1874\u20132071 (2023).","journal-title":"J. Hypertens."},{"key":"74003_CR2","doi-asserted-by":"crossref","unstructured":"Whelton, P. K. et al. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS. A\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 324, ;71:1269 (2017) APh. (2018).","DOI":"10.1161\/HYP.0000000000000076"},{"key":"74003_CR3","doi-asserted-by":"crossref","unstructured":"Unger, T. et al. International Society of Hypertension global hypertension practice guidelines. J. Hypertens. 38, 982\u20131004 (2020). (2020).","DOI":"10.1097\/HJH.0000000000002453"},{"key":"74003_CR4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"SPRINT Research Group","year":"2015","unstructured":"SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl. J. Med.373, 2103\u20132116 (2015).","journal-title":"N Engl. J. Med."},{"key":"74003_CR5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl. J. Med.385, 1268\u20131279 (2021).","journal-title":"N Engl. J. Med."},{"key":"74003_CR6","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1185\/03007990903251193","volume":"25","author":"H Schunkert","year":"2009","unstructured":"Schunkert, H. et al. Efficacy and tolerability of amlodipine\/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy. Curr. Med. Res. Opin.25, 2655\u20132662 (2009).","journal-title":"Curr. Med. Res. Opin."},{"key":"74003_CR7","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.clinthera.2011.11.007","volume":"33","author":"SM Kang","year":"2011","unstructured":"Kang, S. M. et al. Comparative efficacy and safety profile of amlodipine 5\u00a0mg\/losartan 50-mg fixed-dose combination and amlodipine 10\u00a0mg monotherapy in hypertensive patients who respond poorly to amlodipine 5\u00a0mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study. Clin. Ther.33, 1953\u20131963 (2011).","journal-title":"Clin. Ther."},{"key":"74003_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00044011-200929070-00001","volume":"29","author":"V Barrios","year":"2009","unstructured":"Barrios, V., Brommer, P., Haag, U., Calder\u00f3n, A. & Escobar, C. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29, 427\u2013439 (2009).","journal-title":"Clin. Drug Investig"},{"key":"74003_CR9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCULATIONAHA.108.830299","volume":"120","author":"G Mazzaglia","year":"2009","unstructured":"Mazzaglia, G. et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 120, 1598\u20131605 (2009).","journal-title":"Circulation"},{"key":"74003_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","volume":"69","author":"P Gupta","year":"2017","unstructured":"Gupta, P. et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 69, 1113\u20131120 (2017).","journal-title":"Hypertension"},{"key":"74003_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1586\/erc.11.90","volume":"9","author":"Z Khawaja","year":"2011","unstructured":"Khawaja, Z. & Wilcox, C. S. An overview of candesartan in clinical practice. Expert Rev. Cardiovasc. Ther.9, 975\u2013982 (2011).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"Suppl 1","key":"74003_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000175050","volume":"80","author":"DR Abernethy","year":"1992","unstructured":"Abernethy, D. R. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology. 80 (Suppl 1), 31\u201336 (1992).","journal-title":"Cardiology"},{"key":"74003_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/eurheartj\/ehy504","volume":"40","author":"R Ferrari","year":"2019","unstructured":"Ferrari, R. et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur. Heart J.40, 190\u2013194 (2019).","journal-title":"Eur. Heart J."},{"key":"74003_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3109\/10641963.2012.732641","volume":"35","author":"HA Punzi","year":"2013","unstructured":"Punzi, H. A. et al. The effects of telmisartan and amlodipine in Treatment-Na\u00efve and Previously Treated Hypertensive Patients: a subanalysis from 4X4 Factorial Design Study. Clin. Exp. Hypertens.35, 330\u2013340 (2013).","journal-title":"Clin. Exp. Hypertens."},{"key":"74003_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1185\/03007995.2010.487391","volume":"26","author":"YN Ke","year":"2010","unstructured":"Ke, Y. N. et al. Efficacy and safety of a single-pill combination of amlodipine\/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr. Med. Res. Opin.26, 1705\u20131713 (2010).","journal-title":"Curr. Med. Res. Opin."},{"key":"74003_CR16","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 360, 1903\u20131913 (2002).","journal-title":"Lancet"},{"key":"74003_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad, D. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 387, 957\u2013967 (2016).","journal-title":"Lancet"},{"key":"74003_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40885-023-00243-8","volume":"29","author":"HC Kim","year":"2023","unstructured":"Kim, H. C. et al. Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly. Clin. Hypertens.29, 22 (2023).","journal-title":"Clin. Hypertens."},{"key":"74003_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer, M. A. et al. Effects of Candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 362, 759\u2013766 (2003).","journal-title":"Lancet"},{"key":"74003_CR20","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","volume":"110","author":"JB Young","year":"2004","unstructured":"Young, J. B. et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 110, 2618\u20132626 (2004).","journal-title":"Circulation"},{"key":"74003_CR21","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund, L. H. et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur. J. Heart Fail.20, 1230\u20131239 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"74003_CR22","doi-asserted-by":"publisher","first-page":"b5465","DOI":"10.1136\/bmj.b5465","volume":"340","author":"NC Li","year":"2010","unstructured":"Li, N. C. et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 340, b5465 (2010).","journal-title":"BMJ"},{"key":"74003_CR23","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","volume":"34","author":"J Schrader","year":"2003","unstructured":"Schrader, J. et al. The ACCESS study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 34, 1699\u20131703 (2003).","journal-title":"Stroke"},{"key":"74003_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.amjcard.2010.05.007","volume":"106","author":"J Yamaguchi","year":"2010","unstructured":"Yamaguchi, J. et al. Effect of amlodipine\u2009+\u2009candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from the heart institute of Japan Candesartan randomized trial for evaluation in coronary artery disease [HIJ-CREATE] study). Am. J. Cardiol.106, 819\u2013824 (2010).","journal-title":"Am. J. Cardiol."},{"key":"74003_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1586\/erc.12.34","volume":"10","author":"S Yasuno","year":"2012","unstructured":"Yasuno, S., Fujimoto, A., Nakagawa, Y., Kuwahara, K. & Ueshima, K. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev. Cardiovasc. Ther.10, 577\u2013583 (2012).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"74003_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12325-010-0002-0","volume":"27","author":"R Fogari","year":"2010","unstructured":"Fogari, R. et al. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Adv. Ther.27, 48\u201355 (2010).","journal-title":"Adv. Ther."},{"key":"74003_CR27","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen, C. E. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 321, 1440\u20131444 (2000).","journal-title":"BMJ"},{"key":"74003_CR28","first-page":"1557","volume":"60","author":"PML Vanderheyden","year":"2000","unstructured":"Vanderheyden, P. M. L., Fierens, F. L. P. & Vauquelin, G. Angiotensin II type 1receptor antagonists. Why some Them Produce Insurmountable Inhib. ? Biochem. Pharmacol.60, 1557 (2000).","journal-title":"Why some Them Produce Insurmountable Inhib. ? Biochem. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74003-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74003-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74003-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:52:22Z","timestamp":1727927542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74003-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74003"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74003-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"19 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by HK inno.N Corp. (formerly CJ Healthcare), Seoul, Korea. The sponsor was responsible for data collation and statistical analysis, which was supported by Chung Hyun Choi, an employee of HK inno.N Corp. Soohong Kim, an employee of HK inno.N Corp., assisted with the preparation of the manuscript, but did not meet the criteria for authorship. The authors declare no other competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22940"}}